Evofem Biosciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Evofem Biosciences, Inc.

Evofem Biosciences, Inc. is a U.S.-based biopharmaceutical company headquartered in San Diego, California, United States. From an investor perspective, it is a niche commercial-stage women’s health company with a focused, high-risk/high-reward profile rather than a broad diversified pharma platform. The company is listed in the U.S. market on OTCID/OTC under the ticker EVFM, and its business model is centered on commercializing sexual and reproductive health products for women. Founded in 2007, Evofem was built around the objective of addressing under-served needs in contraception and sexually transmitted infection care, with an emphasis on innovative, woman-controlled solutions. Its current revenue base is anchored by two FDA-approved products: PHEXXI, a hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC (secnidazole) 2g oral granules, a single-dose oral treatment for trichomoniasis and bacterial vaginosis. These products give Evofem a distinct commercial identity in a crowded healthcare landscape: rather than competing head-on with large pharmaceutical companies on scale, it competes on differentiation, convenience, and physician education within women’s health. The company’s commercial footprint is primarily in the United States, where it markets to OB/GYN physicians and focuses on prescription-driven demand. Outside the U.S., Evofem has begun expanding through licensing partnerships, including arrangements in the Middle East and North Africa, which may provide optionality for future geographic expansion without the capital intensity of a large direct-sales buildout. Recent company highlights are material for equity analysis. In 2025 and into early 2026, Evofem reported continued net sales growth, including a fifth consecutive year of sales growth in 2025 and record annual net sales, while also pursuing cost-reduction initiatives and working to improve the manufacturing economics of its portfolio. At the same time, the investment case remains constrained by financing risk, liquidity pressure, and ongoing going-concern considerations, which are critical for valuation and downside assessment. The result is a small-cap healthcare story with clear product differentiation, a concentrated commercial base, and meaningful execution risk. For French-speaking investors, Evofem should be viewed as a specialized U.S. women’s health platform whose upside depends on sustaining U.S. product momentum, expanding selectively overseas, and maintaining access to capital on acceptable terms.